Study of 4, 6-0-Benzylidene-D-glucopyranose in Cancer Treatment
Author Information
Author(s): T. Tatsumura, M. Tsujimoto, S. Koyama, T. Furuno, Y. Komori, H. Sato, K. Yamamoto, M. Kitagawa, S. Kagamimori
Primary Institution: Toyama Medical and Pharmaceutical University
Hypothesis
Can 4, 6-0-Benzylidene-D-glucopyranose (BG) effectively treat various solid malignant tumors?
Conclusion
The study found that BG showed anti-tumor responses in 41.7% of patients with solid malignant tumors, with no observed toxicity.
Supporting Evidence
- 10 out of 24 patients showed a response to BG treatment.
- 2 patients had a complete response, and 8 had a partial response.
- Overall response rate was 58.3%, with 41.6% considering only complete and partial responses.
- No significant toxicity was observed during the treatment.
- Marked improvement in performance status was noted in patients who responded to treatment.
Takeaway
This study tested a new treatment for cancer called BG, and it helped some patients without making them sick.
Methodology
24 patients with advanced stage carcinomas were treated with BG and monitored for responses and side effects over two months.
Limitations
The study had a small sample size and was limited to a short treatment duration.
Participant Demographics
20 male and 4 female patients, average age 63.6 years, ranging from 11 to 86 years old.
Want to read the original?
Access the complete publication on the publisher's website